Phase 1 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 65 years old at the time of signing the consent form
- People who are willing and able to sign a consent form agreeing to take part
- People diagnosed with dilated cardiomyopathy (a condition where the heart is enlarged and does not pump well), with a heart pumping function that is reduced but not severely so — specifically, a measurement called ejection fraction between 25% and 45%, confirmed by a heart scan within the past 3 months
- People whose heart pumping problems are not caused by a significant blockage in the heart's arteries (more than 70% blocked) or by active reduced blood flow to the heart muscle
- People whose heart condition is not caused by uncontrolled high blood pressure, a significant heart valve problem, or certain other known diseases that can affect the heart muscle
- People who have a confirmed or likely harmful change (variant) in a gene called BAG3
- People who have had an implanted heart device (a defibrillator, sometimes called an ICD) for at least 3 months before joining
- People with mild to moderate heart failure symptoms (known as NYHA Class II or III), who have been on a stable heart failure medication plan for at least 30 days before joining
Who may not be able to join:
- People whose heart disease may be linked to a different genetic cause, other than a BAG3 gene variant
- People who have previously taken part in a study involving gene therapy or gene editing
- People who have received certain medicines given directly into a vein — specifically, medicines to support the heart's pumping, widen blood vessels, or remove fluid — within the 30 days before joining
- People with a history of blood clots inside the heart or clots that have travelled through the arteries
- People with severely reduced function of the right side of the heart, confirmed by a heart scan within the past 12 months
- People whose heart pumping function measurement (ejection fraction) is below 25%, confirmed by a heart scan within the past 3 months
- People with either very mild heart failure symptoms (NYHA Class I) or very severe heart failure symptoms (NYHA Class IV)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 646-627-0033
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Treatment-emergent Adverse Events (TEAE); Incidence of Treatment-emergent Serious Adverse Events (SAE).; Incidence of Dose Limiting Toxicities (DLT).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.